Predictive Oncology, Inc. (NASDAQ: POAI) operates as an artificial intelligence-driven biotechnology company focused on accelerating the discovery and development of novel cancer therapies. The company combines proprietary machine-learning algorithms with high-throughput phenotypic screening and organoid-based models to identify promising drug candidates and predictive biomarkers. By integrating vast datasets from cellular imaging, genomic profiling and clinical outcomes, Predictive Oncology seeks to shorten development timelines and improve the likelihood of clinical success.
At the core of Predictive Oncology’s offering is its OncoPredict platform, which employs three-dimensional patient-derived tumor organoids to replicate the tumor microenvironment more accurately than traditional cell lines. This approach allows for rapid assessment of compound efficacy and safety, as well as identification of drug repositioning opportunities. In parallel, the company’s Qrativ™ joint venture, created in partnership with a major life sciences investor, uses AI-powered target identification and validation to advance small-molecule immuno-oncology programs toward the clinic.
Founded in the mid-2010s and headquartered in Columbia, Maryland, Predictive Oncology maintains operations in the United States, Europe and Asia to support collaborative research efforts and access global patient data. Over the years, the company has forged partnerships with academic institutions, contract research organizations and pharmaceutical companies to expand its pipeline and validate its platforms. These collaborations have resulted in licensing agreements and sponsored research programs aimed at tackling high-unmet-need cancers.
Predictive Oncology is led by a seasoned management team with deep expertise in drug discovery, translational oncology and computational biology. Under their guidance, the company has continued to refine its platforms, pursue strategic collaborations and explore opportunities in precision medicine. Moving forward, Predictive Oncology plans to leverage its AI-driven capabilities to deliver differentiated oncology assets and advance personalized treatment strategies.
AI Generated. May Contain Errors.
